A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Not yet recruiting · NCT06364904 · Registry updated 2025-02-21

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder	Not yet recruiting	Phase 3	2025-02-21		NCT06364904

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	285

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Hunan Cancer Hospital	Changsha	China	87
Nanfang Hospital, Southern Medical University	Guangzhou	China	33
Sun Yat-sen Memorial Hospital	Guangzhou	China	16
The First Affiliated Hospital of Sun Yat-sen University	Guangzhou	China	18
The Third Affiliated Hospital of Sun Yat-sen University	Guangzhou	China	17
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	20
Xiangya Hospital, Central South University	Changsha	China	14
ZhuJiang Hospital of Southern Medical University	Guangzhou	China	27